Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Homo sapiens

ABSTRACT: RNA-seq analysis of various colon cancer cell lines with TET2 overexpression

PROVIDER: PRJNA394065 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5821830.fastq.gz	Fastqsanger.gz
	SRR5821831.fastq.gz	Fastqsanger.gz
	SRR5821832.fastq.gz	Fastqsanger.gz
	SRR5821833.fastq.gz	Fastqsanger.gz
	SRR5821834.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 9

Similar Datasets

WGBS analysis of various colon cancer cell lines

Project description:WGBS analysis of various colon cancer cell lines

| PRJNA647354 | ENA

RNA-seq analysis of various colon cancer cell lines treated with TGFb1 and repsox

Project description:RNA-seq analysis of various colon cancer cell lines treated with TGFb1 and repsox

| PRJNA646945 | ENA

Homo sapiens

Project description:RNA-seq of HCT116 and HCT116-DKO colon cancer cell lines

| PRJNA324686 | ENA

5-hydroxymethylcytosine marks promoters in colon that resist hypermethylation in cancer [seq]

Project description:The discovery of cytosine hydroxymethylation (5-hmC) as a mechanism that potentially controls DNA methylation changes typical of neoplasia prompted us to investigate its behavior in colon cancer. 5-hmC is globally reduced in proliferating cells such as colon tumors and the gut crypt progenitors, from which tumors can arise. Here, we show that colorectal tumors and cancer cells express Ten-Eleven Translocation (TET) transcripts at levels similar to normal tissues. Genome-wide analyses show that promoters marked by 5-hmC in normal tissue, and those identified as TET2 targets in colorectal cancer cells, are resistant to methylation gain in cancer. In vitro studies of TET2 in cancer cells confirm that these promoters are resistant to methylation gain independently of sustained TET2 expression. We also find that a considerable number of the methylation gain-resistant promoters marked by 5-hmC in normal colon overlap with those that are marked with poised bivalent histone modifications in embryonic stem cells. Together our results indicate that promoters that acquire 5-hmC upon normal colon differentiation are innately resistant to neoplastic hypermethylation by mechanisms that do not require high levels of 5-hmC in tumors. Our study highlights the potential of cytosine modifications as biomarkers of cancerous cell proliferation. 5 normal colon samples and 4 matching tumor samples were profiled for 5-hydroxymethylcytosine content genomewide using hmeDIP-seq. The colorectal cancer cell line HCT116 was profiled for binding of TET2 genomewide by chromatin immunoprecipitation sequencing (ChIP-seq).

2015-02-03 | E-GEOD-47590 | biostudies-arrayexpress

Homo sapiens

Project description:RNA-Seq analysis of human medulloblastoma cell lines with SOX9 overexpression

| PRJNA328820 | ENA

Homo sapiens

Project description:Gene expression analysis following JQ1 treatments in colon cancer lines

| PRJNA296592 | ENA

5-hydroxymethylcytosine marks promoters in colon that resist hypermethylation in cancer [ExpressionArray]

Project description:The discovery of cytosine hydroxymethylation (5-hmC) as a mechanism that potentially controls DNA methylation changes typical of neoplasia prompted us to investigate its behavior in colon cancer. 5-hmC is globally reduced in proliferating cells such as colon tumors and the gut crypt progenitors, from which tumors can arise. Here, we show that colorectal tumors and cancer cells express Ten-Eleven Translocation (TET) transcripts at levels similar to normal tissues. Genome-wide analyses show that promoters marked by 5-hmC in normal tissue, and those identified as TET2 targets in colorectal cancer cells, are resistant to methylation gain in cancer. In vitro studies of TET2 in cancer cells confirm that these promoters are resistant to methylation gain independently of sustained TET2 expression. We also find that a considerable number of the methylation gain-resistant promoters marked by 5-hmC in normal colon overlap with those that are marked with poised bivalent histone modifications in embryonic stem cells. Together our results indicate that promoters that acquire 5-hmC upon normal colon differentiation are innately resistant to neoplastic hypermethylation by mechanisms that do not require high levels of 5-hmC in tumors. Our study highlights the potential of cytosine modifications as biomarkers of cancerous cell proliferation. messenger RNA levels were measured in total RNA extracted from primary colon tissues. Normal away are at least 20cm from tumors.

2015-02-03 | E-GEOD-47063 | biostudies-arrayexpress

Project description:RNA Seq analysis of sorghum SbMyb60 overexpression lines

| PRJNA327395 | ENA

Epitranscriptome profiling of m6A in colon cancer cell lines

Project description:N6-methyl adenosine (m6A) is one of the most important RNA modifications involved in several biological and pathological processes, including cancer. Dysregulation of m6A has been linked with tumor initiation, progression, and metastasis of several cancer types, including colon cancer. A transcriptome of colon cancer describes the dysregulated coding and non-coding RNAs but does not reveal the mechanisms like m6A modifications that determine the post-transcriptional and pre-translational regulations. Epi-transcriptome profiling of m6A in colon cancer cell lines was performed using Methylated RNA Immunoprecipitation (MeRIP) sequencing. Overall, the study illustrates the distribution of m6A across the transcriptome of various colon cancer cell lines.

2023-12-30 | GSE240438 | GEO

Homo sapiens

Project description:RNA-seq analysis upon ARID1B overexpression

| PRJNA303112 | ENA